ZNTL Stock Forecast: Zentalis Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.36
0.00% on the day

The median 12-month analyst price target for Zentalis Pharmaceuticals, Inc. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 44 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$133.6M
Ticker Nerd rank
44/ 100
Median analyst target
$7.00
Analysts covering
11
Revenue$0.0
Operating income−$44.4M
Net income−$42.3M
Free cash flow−$37.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−20.0%
1M
−43.1%
YTD
+0.7%
1Y
+4.6%
From 52W high
−79.4%
From 52W low
+4.6%
$1.30
$6.61
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Zentalis Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
44/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
67
Revisions
62
Momentum
61
Quality
48
Issuance
47
Growth
31
Value
22
Volatility
12

Accruals (67): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (12): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ZNTL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZNTL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26ZNTLHigh $10.00Median $7.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
9
Buy
2
Hold
0
Sell
$5.00
Low
$7.00
Median
$10.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Nov 2026WedbushUpgradeOutperform$5.00 → $6.00
19 Oct 2026HC Wainwright & Co.ReiteratesBuy$10
5 Oct 2026Leerink PartnersAssumesOutperform$4.00 → $8.00
16 Sept 2026William BlairInitiatesOutperform—
23 July 2026Rodman & RenshawInitiatesBuy—
17 July 2026MizuhoInitiatesOutperform$8.00
10 Apr 2026GuggenheimMaintainsBuy—
27 Mar 2026GuggenheimReiteratesBuy—
12 Nov 2025Morgan StanleyMaintainsEqual-Weight—
7 Aug 2025Wells FargoMaintainsEqual-Weight—
15 May 2025HC Wainwright & Co.ReiteratesBuy—
15 May 2025WedbushReiteratesNeutral—
28 Mar 2025WedbushReiteratesNeutral—
27 Mar 2025HC Wainwright & Co.ReiteratesBuy—
17 Mar 2025HC Wainwright & Co.ReiteratesBuy—
30 Jan 2025Wells FargoMaintainsEqual-Weight—
29 Jan 2025HC Wainwright & Co.MaintainsBuy—
28 Jan 2025UBSMaintainsNeutral—
15 Nov 2024GuggenheimMaintainsBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ZNTL.

Market Radar

This page is one stock. Monday covers all of them.

ZNTL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ZNTL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Zentalis Pharmaceuticals, Inc. returned +4.6% against +6.9% for the S&P 500, dividends included.

ZNTL vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Jan 26Apr 26Jul 26Oct 26ZNTLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ZNTL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.7×

Cheaper than 82% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−61.9%

Higher than 19% of US stocks

Return on assets
−30.9%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Zentalis Pharmaceuticals, Inc. has a market value of $133.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$139.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$128.1M.

  • Shares outstanding: 71.7M.

  • Zentalis Pharmaceuticals, Inc. employs 106 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ZNTL and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ZNTLZentalis Pharmaceuticals, Inc.$133.6M44
SIONSionna Therapeutics, Inc.$126.1M21
MGNXMacroGenics, Inc.$124.6M85
PYPDPolyPid Ltd.$124.3M51
CMPXCompass Therapeutics, Inc.$123.9M29
TARAProtara Therapeutics, Inc.$134.7M26
IVVDInvivyd, Inc.$121.6M22

Take a look at ZNTL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Zentalis Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ZNTL

What is the ZNTL stock price forecast for 2026-2027?

The median 12-month analyst price target for Zentalis Pharmaceuticals, Inc. is $7, with estimates ranging from $5 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ZNTL stock a buy right now?

Of the 11 analysts covering Zentalis Pharmaceuticals, Inc., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zentalis Pharmaceuticals, Inc. 44 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ZNTL?

As at 21 Nov 2026, Zentalis Pharmaceuticals, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (67 of 100).

Will ZNTL stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts is $7, and Ticker Nerd's factor model ranks Zentalis Pharmaceuticals, Inc. 44 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ZNTL stock forecast for 2030?

No analyst covering Zentalis Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZNTL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $10 over the next 12 months.

How has ZNTL stock performed over the past year?

Zentalis Pharmaceuticals, Inc. returned +4.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Zentalis Pharmaceuticals, Inc. do?

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer. Its current portfolio centers on azenosertib, an oral investigational WEE1 inhibitor being advanced in studies across ovarian cancer and other solid tumors.

Company

About Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer. Its current portfolio centers on azenosertib, an oral investigational WEE1 inhibitor being advanced in studies across ovarian cancer and other solid tumors. The company’s research emphasizes biomarker-driven oncology, with a focus on targeted, non-chemotherapy treatment approaches designed to address difficult-to-treat cancers. Zentalis also develops additional oncology candidates, including programs targeting hematologic malignancies and other cancer pathways, supported by its internal discovery capabilities and clinical development expertise. Headquartered in San Diego, California, Zentalis Pharmaceuticals plays a specialized role in the oncology market by advancing precision medicine candidates from discovery into late-stage clinical evaluation.

CEO Ms. Julie M. Eastland M.B.A. · 106 employees · United States · https://zentalis.com